Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02167854
Title Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Alpelisib + Elgemtumab + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST